BioNTech said in 2022 that it faced “threats of a groundless patent infringement suit” from a company that was “unable to ...

The Ministry of Health has announced that the updated Pfizer-BioNTech Covid-19 vaccine, targeting the JN.1 variant, is now available in Bermuda by appointment. A Government spokesperson said, “The ...

An updated Pfizer-BioNTech Covid-19 vaccine, designed to target the JN.1 variant of the virus circulating globally, is now ...

Robert F. Kennedy Jr., in an opinion piece published in the Wall Street Journal, outlined the reasons for the overhaul, stating that the committee had become a "rubber stamp" for vaccine approval ...

BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech ...

Following a disappointing performance from the company’s CAR-T candidate in an early-stage cancer trial, BioNTech is winding down cell therapy manufacturing at its inaugural U.S. plant. | Following a ...

Valued at $1.25 billion, the deal expands BioNTech’s cancer drug portfolio and heads off royalty costs it could have owed ...

(Reuters) -Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune ...

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, the companies said Thursday, bringing together two ...

German pharmaceutical firm BioNTech, one of the first companies worldwide to develop an effective coronavirus vaccine, is looking to acquire its domestic rival CureVac, the firm said on Thursday.

CureVac about a year ago opted to focus on oncology when it agreed to sell its remaining influenza and COVID-19 vaccine ...